EDP Sciences logo
Web of Conferences logo
Search
Menu
All issues Volume 185 (2020) E3S Web Conf., 185 (2020) 03006 References
Open Access
Issue
E3S Web Conf.
Volume 185, 2020
2020 International Conference on Energy, Environment and Bioengineering (ICEEB 2020)
Article Number 03006
Number of page(s) 6
Section Medical Biology and Medical Signal Processing
DOI https://doi.org/10.1051/e3sconf/202018503006
Published online 01 September 2020
  1. Lawal, M., Omobayo, H., & Lawal, K. Epilepsy: pathophysiology, clinical manifestations and treatment options. British Journal of Neuroscience Nursing, 14(2), 58–72 (2018) [CrossRef] [Google Scholar]
  2. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators.Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. (2016) [Google Scholar]
  3. Falco-Walter, J. J.; Scheffer, I. E.; Fisher, R. S. The New Definition and Classification of Seizures and Epilepsy. Epilepsy Research, 139, 73–79, (2018) [CrossRef] [PubMed] [Google Scholar]
  4. Zhang, X., Li, X., Liu, N., Zheng, P., Ma, L., Guo, F., … & Yu, J. The Anticonvulsant Effects of Baldrinal on Pilocarpine-Induced convulsion in Adult Male Mice. Molecules, 24(8), 1617, (2019) [Google Scholar]
  5. Stafstrom, C. E.; Carmant, L. Seizures and Epilepsy: An Overview for Neuroscientists. Cold Spring Harbor Perspectives in Medicine, 5(6), (2016) [Google Scholar]
  6. Sheng, J.; Liu, S.; Qin, H.; Li, B.; Zhang, X. Drug- Resistant Epilepsy and Surgery. Current Neuropharmacology, 16 (1), (2017) [Google Scholar]
  7. Eadie, M. J. Shortcomings in the Current Treatment of Epilepsy. Expert Review of Neurotherapeutics, 12 (12), 1419–1427, (2012) [CrossRef] [PubMed] [Google Scholar]
  8. Naghavi, M. Global, Regional, and National Burden of Suicide Mortality 1990 to 2016: Systematic Analysis for the Global Burden of Disease Study 2016. Bmj, l94, (2019) [Google Scholar]
  9. Anam, S.; Hunter, S.; Afzal, K. The Effects of Antiepileptic Drugs on Pediatric Cognition, Mood, and Behavior. Journal of Pediatric Epilepsy, 06 (01), 003–018, (2016) [Google Scholar]
  10. Dalic, L.; Cook, M. Managing Drug-Resistant Epilepsy: Challenges and Solutions. Neuropsychiatric Disease and Treatment, 12, 2605–2616, (2016) [CrossRef] [PubMed] [Google Scholar]
  11. Jacob,S.; Nair A. B. An Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic Drugs. Drugs R&D, 16, 303–316, (2016) [CrossRef] [Google Scholar]
  12. French, J, A. New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety? Therapeutic Advances in Drug Safety, 2(4), 141–158, (2011) [CrossRef] [PubMed] [Google Scholar]
  13. Emilio, P., and Svein, J. I. The ideal pharmacokinetic properties of an anti-epileptic drug: how close does levetiracetam come? Disord, 5, 17–26, (2003) [Google Scholar]
  14. Keppra XR [Package insert]. Smyrna, GA: UCB Pharma, Inc, (2008) [Google Scholar]
  15. Song, L., Shemchuk, O., Robeyns, K., Braga, D., Grepioni, F., and Leyssens, T. Ionic Cocrystals of Etiracetam and Levetiracetam: The Importance of Chirality for Ionic Cocrystals. Crystal Growth & Design, 19, 2446–2454, (2019) [Google Scholar]
  16. Brittain, H. G. Profiles of drug substances, excipients, and related methodology. Academic Press, imprint of ElsevierCambridge, MA, (2018) [Google Scholar]
  17. Grace, A. C., Prabha, T., Jagadeeswaran, M., Srinivasan, K., and Sivakumar, T. Simultaneous Estimation of Levetiracetam and its Preservatives In Oral Liquid Dosage form by Rp-Hplc Method. SOJ Materials Science & Engineering, 4, 1–5, (2016) [CrossRef] [Google Scholar]
  18. M.J. O’Neil. The Merck Index—An Encyclopedia of Chemicals, Drugs, and Biologicals, Whitehouse Station,13 p. 978, (2001) [Google Scholar]
  19. Sivaneswari, S., Karthikeyan, E., Veena, D., Chandana, P. J., Sai, P. S., Subhashree, P., Ramya, L., Rajalakshmi, R., and Ashok, C. K. K. Physiochemical characterization of taste masking levetiracetam ion exchange resinates in the solid state and formulation of stable liquid suspension for pediatric use. Beni-Suef University Journal of Basic and Applied Sciences, 5, 126–133, (2016) [Google Scholar]
  20. J. Gobert, J.-P. Geerts, G. Bodson. (S)-α-ethyl-2- oxo-l-pyrrolidineacetamide Compositions, US Patent 4943639A, (1985) [Google Scholar]
  21. Gower, A. J., Noyer, M., Verloes, R., Gobert, J., and Wülfert, E. ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. European Journal of Pharmacology 230, 389, (1993) [Google Scholar]
  22. Zhou, X., Xu, G., Zhou, Y., Xu, M. Synthesis of Anticonvulsant Drug Levetiracetam[J]. Fine Chemical Intermediates, 35(3), 27–28, (2005) [Google Scholar]
  23. Shen, L., Bian, Y., Liu, F., Wu, P., Jiang, K. A method for preparing levetiracetam[P]. 200910026351.9, (2009) [Google Scholar]
  24. Ate C, Surtees J, Burteau A-C, et al. Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues.US Patent WO03014080, (2003) [Google Scholar]
  25. Boschi F, Camps P, Comes-Franchini M. A synthesis of levetiracetam based on (S)-N- phenylpantolactam as a chiral auxiliary[J]. Tetrahedron: Asymmetry, 16(22): 3739–3745, (2005) [CrossRef] [Google Scholar]
  26. Kotkar S P, Sudalai A. A short enantioselective synthesis of the antiepileptic agent, levetiracetam based on proline-catalyzed asymmetric α- aminooxylation[J]. Tetrahedron Letters. 47(38): 6813–6815, (2006) [Google Scholar]
  27. Surtees J, Marmon V, Differding E. 2-Oxo-1- pyrrolidine derivatives, process for preparing them and their uses: US6,713,635[P], (2004) [Google Scholar]
  28. Browne, T. R. Pharmacokinetics of anti-epileptic drugs. Neurology, 51(5 Suppl 4), 2–7, (1998) [Google Scholar]
  29. Wright, C., Downing, J., Mungall, D., Khan, O., Williams, A., Fonkem, E., Garrett, D., Aceves, J., and Kirmani, B. Clinical Pharmacology and Pharmacokinetics of Levetiracetam. Frontiers in Neurology 4, (2013) [Google Scholar]
  30. Patsalos, P. Pharmacokinetic profile of levetiracetam. Pharmacology & Therapeutics, 85, 77–85, (2000) [CrossRef] [PubMed] [Google Scholar]
  31. Abou-Khalil. B. Levetiracetam in the Treatment of Epilepsy. Neuropsychiatric Disease and Treatment, 507, (2008) [Google Scholar]
  32. Zona, C., Niespodziany, I., Marchetti, C., Klitgaard, H., Bernardi, G., and Margineanu, D. G. Levetiracetam does not modulate neuronal voltage- gated Na and T-type Ca2 currents. Seizure, 10, 279–286, (2001) [CrossRef] [PubMed] [Google Scholar]
  33. Klitgaard, H. Levetiracetam: The Preclinical Profile of a New Class of Anti-epileptic Drugs Epilepsia 42,13–18, (2001) [Google Scholar]
  34. Madeja, M., Margineanu, D. G., Gorji, A., Siep, E., Boerrigter, P., Klitgaard, H., and Speckmann, E.-J. Reduction of voltage-operated potassium currents by Levetiracetam: a novel anti-epileptic mechanism of action? Neuropharmacology, 45, 661–671, (2003) [CrossRef] [PubMed] [Google Scholar]
  35. Rajakulendran, S., and Hanna, M. G. The Role of Calcium Channels in Epilepsy. Cold Spring Harbor Perspectives in Medicine, 6, (2016) [Google Scholar]
  36. Lukyanetz, E., Shkryl, V., and Kostyuk, P. Selective Blockade of N-Type Calcium Channels by Levetiracetam. Epilepsia, 43, 9–18, (2002) [Google Scholar]
  37. Rigo, J.-M., Hans, G., Nguyen, L., Rocher, V., Belachew, S., Malgrange, B., Leprince, P., Moonen, G., Selak, I., Matagne, A., and Klitgaard, H. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. British Journal of Pharmacology, 136, 659–672, (2002) [CrossRef] [PubMed] [Google Scholar]
  38. Sharief, M., Singh, P., Sander, J., Patsalos, P., and Shorvon, S. Efficacy and tolerability study of ucb L059 in patients with refractory epilepsy. Journal of Epilepsy, 9, 106–112, (1996) [Google Scholar]
  39. Klitgaard, H., Matagne, A., Gobert, J., and Wülfert, E. Evidence for a unique profile of Levetiracetam in rodent models of seizures and epilepsy. European Journal of Pharmacology, 353, 191–206, (1998) [CrossRef] [PubMed] [Google Scholar]
  40. Cereghino, J. J., Biton, V., Abou-Khalil, B., Dreifuss, F., Gauer, L. J., and Leppik, I. Levetiracetam for partial seizures: Results of a double-blind, randomized clinical trial. Neurology, 55, 236–242, (2000) [Google Scholar]
  41. Brockmoller, J., Thomsen, T., Wittstock, M., Coupez, R., Lochs, H., and Roots, I. Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): Characterization by dynamic liver function tests. Clinical Pharmacology & Therapeutics, 77, 529–541, (2005) [CrossRef] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.